Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TRANSCRANIAL MAGNETIC THERAPY (TMS) FOR TREATMENT OF PERINATAL DEPRESSION

NCT07928908 is registered in ClinicalTrials.gov with Rana Jawish as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07928908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
TRANSCRANIAL MAGNETIC THERAPY (TMS) FOR TREATMENT OF PERINATAL DEPRESSION
Lead sponsor
Rana Jawish
Phase
Not applicable
Overall status
Active, not recruiting
Start date
September 23, 2026
Completion date
May 31, 2029
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

perinatal depression

Arms

As registered; 1 arm.

  • Transcranial Magnetic Stimulation ExperimentalTranscranial Magnetic Stimulation (TMS)

    All participants will receive active transcranial magnetic stimulation (TMS) targeting the left dorsolateral prefrontal cortex (DLPFC) using the NeuroStar TMS system. Treatment will consist of standard repetitive TMS (10 Hz) or intermittent theta burst stimulation (iTBS), delivered at 120% of the individual's resting motor threshold. Participants will receive one treatment session per day, up to five days per week, for a total of 20-36 sessions over approximately 4-8 weeks. Participants who achieve remission after completing at least 20 sessions may end treatment, while those who have not achieved remission may continue treatment for up to 36 sessions. All participants will be monitored for safety and clinical response throughout treatment.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Retention Rate 8 weeks post baseline

    Proportion of participants who complete at least 20 TMS treatment sessions.

Similar trials

Same condition (Depression, Postpartum) and phase, most recent start first.